Genetic epilepsy with febrile seizures plus …

Epilepsy & Seizures

Updated 09.09.2023
Released 09.02.2004
Expires For CME 09.09.2026

Genetic epilepsy with febrile seizures plus

Authors: Eleni Panagiotakaki MD PhD, Maria Papadopoulou MD, Alexis Arzimanoglou MD

See Contributor Disclosures

Editor: Jerome Engel Jr MD PhD

Genetic epilepsy with febrile seizures plus

In This Article

Quick Link

Introduction

Overview

Genetic epilepsy with febrile seizures plus (GEFS+) is a familial epileptic syndrome characterized by occurrence of seizures in multiple family members with important phenotypical heterogeneity. The phenotypical spectrum usually includes febrile seizures or febrile seizures plus but various types of seizures/epileptic syndromes could be observed in at least two family members. The initial description included afebrile generalized tonic-clonic seizures that extended into late childhood following febrile seizures. The syndrome was thus referred to as “generalized epilepsy with febrile seizures plus”; however, the term “genetic epilepsy” is now preferred due to the presence of focal as well as generalized seizures in some patients. Other seizure types include myoclonic attacks, myoclonic-astatic seizures, absences, and focal seizures. At the severe end of the spectrum lie epileptic encephalopathies, such as Dravet syndrome and myoclonic-atonic epilepsy. EEG patterns and drug responsiveness depend on seizure type and clinical phenotype. The inheritance follows a complex pattern that was initially considered as autosomal dominant with incomplete penetrance; subsequent data also suggest polygenic, recessive inheritance and de novo mutations that encode in the majority of cases of ion channel subunits. Neurodevelopment, apart from severe cases of epileptic encephalopathies, is usually normal.

Key points

	• Genetic epilepsy with febrile seizures plus (GEFS+) is an epileptic condition characterized by the occurrence of febrile seizures and a variety of other seizures types (febrile seizures plus, nonfebrile seizures, generalized, or focal) in at least two members of the same family.
	• The clinical presentation of patients with GEFS+ is diverse, and the clinical spectrum extends from familial febrile seizures (least severe cases) to myoclonic-astatic epilepsy or Dravet syndrome (most severe cases).
	• Inheritance is mainly autosomal dominant with incomplete penetrance but other inheritance patterns (recessive, copy number variations, de novo, etc.) have been described.
	• Mutations associated with GEFS+ have been identified in genes that encode for sodium channel subunits (SCN1A, SCN2A, SCN1B, SCN9A) and ligand-gated gamma aminobutyric acid receptor A gamma2 and delta subunits (GABRG2, GABRD), as well as several other genes implicated in epileptogenesis.
	• Management depends on seizure type, or on epileptic syndrome phenotype (ie, stiripentol for Dravet syndrome). In the majority of cases neuroimaging and neurodevelopment are normal.

Historical note and terminology

In 1994, Aicardi initially recognized a subgroup of patients with febrile convulsions followed by infrequent generalized seizures that often remitted definitively by 9 to 12 years of age, suggesting a possible syndrome of childhood epilepsy with generalized tonic-clonic seizures (GTCS) (02).

The term "generalized epilepsy with febrile seizures plus" (GEFS+) was first used by Scheffer and Berkovic to describe "a genetic disorder with heterogeneous clinical phenotypes" (120). The description was based on the recognition that in a large Anglo-Australian extended family of 25 members studied over four generations, febrile seizures, and afebrile generalized seizures of various types appeared to be transmitted as a dominant genetic character.

Twenty-three family members had a history of febrile convulsions that were often prolonged in duration and extended over the age of five years (FS+). Nine individuals had later afebrile seizures of variable severity that started at a median age of 2.2 years and remitted by 11.7 years (range 6 to 25 years). All had normal intellect, and EEGs were normal at last examination. Other seizure types were also present; one proband had myoclonic-astatic epilepsy; four had infrequent absence seizures in addition to FS+, and one man had atonic attacks head falls. Episodes of status epilepticus occurred in some pedigree members. In this family, linkage of the condition to chromosome 19q (19q13.1) was demonstrated (150), and the gene in question was later identified as the beta subunit of the sodium channel SCN1B gene (patients are referred to as GEFS+1).

Other similar pedigrees were reported soon afterwards (97; 136; 18). Linkage to chromosome 2q (2q24) (12) and mutations in the alpha subunit of the sodium channel SCN1A gave rise to GEFS+2 patient group (46; 148). At the same time, other ion-channel associated genes were soon described; patients with mutation in the gamma2 subunit (GABRG2; locus 5q34) and delta subunit (GABRD; 1p36.3) were respectively referred to as GEFS+3 and GEFS+5 (147).

Linkage studies that further identified several genetic loci in patients with features of genetic epilepsy with febrile seizures plus have led so far to the description of 10 GEFS+ subgroups, delineated by their causative gene (see Table 1). The above categorization, targeting to correlate genetic and clinical variability, has over the years been pushed aside by the increasing number of genetic loci, complex inheritance mechanisms, and copy number variations described. However, it could still be used in clinical practice and is worth mentioning.

Reports that patients within genetic epilepsy with febrile seizures plus families could also present with focal seizures as temporal lobe epilepsy (01) or frontal lobe epilepsy (122) came to light in the early 2000s. Scheffer and Berkovic, along with many other experts, thus proposed that GEFS+ should more appropriately referred to as "genetic epilepsy with febrile seizures plus" because both focal and generalized seizures occur in such families (121; 157; 16).

Genetic epilepsy with febrile seizures plus is a difficult to diagnose entity in the sense that the term "syndrome" in this case is used to describe a familial occurrence rather than an association of signs and symptoms in an individual patient (signs and symptoms may vary extensively between patients of the same family). In a report the ILAE Genetics Commission adopted the term “GEFS+ spectrum” for this “genetic syndrome” characterized by phenotypic along with continuously enriched genetic heterogeneity (101). In their articles, experts from China adopted the term “fever-associated seizures or epilepsy” (FASE) in order to refer to all different phenotypes associated with the disorder (30; 42).

Table 1. Genetic Loci and Most Commonly Known Genes Associated with GEFS+

Locus	Gene	GEFS+
19q13.1	SCN1B	GEFS+1 (150)
2q24.3	SCN1A	GEFS+2 (46)
5q34	GABRG2	GEFS+3 (147)
2p24		GEFS+4 (07)
1p36.2	GABRD	GEFS+5 (147)
8p23-21		GEFS+6 (10)
2q24.3-31.1	SCN9A	GEFS+7 (134)
6q16.3-q22.31		GEFS+8 (112)
16p11.2	STX1B	GEFS+9 (127)
5p12	HCN1	GEFS+10 (90)

Clinical manifestations

Presentation and course

Early in the description of the disease it became evident that in the same pedigree of a GEFS+ family, patients express a highly variable phenotype that is generally mild (120). Although the occurrence of GTCS was originally considered a defining characteristic of GEFS+, these are not the only type of seizures observed to date. Indeed, FS+ and afebrile generalized seizures are sometimes associated with absences or atonic, myoclonic, myoclonic-astatic, or focal seizures (157). Xu and colleagues demonstrated this highly heterogeneous spectrum in their report of 39 families with 196 affected members (155). This variable presentation was subsequently further supported by the study of 303 families in which 22 GEFS+ families were described (45), including phenotypes not generally recognized at the time.

Although members of a pedigree may present with well-characterized epilepsy syndromes (myoclonic-astatic epilepsy, Dravet syndrome, temporal lobe epilepsy), others may only have occasional seizures, particularly febrile convulsions. The recognition of GEFS+ is, thus, frequently difficult in clinical practice. At least two members of a family with phenotypes that fall in the GEFS+ spectrum are required for its diagnosis (126). However, de novo pathogenic variants in SCN1A resulting to mild phenotypes reminiscent to the GEFS+ clinical spectrum have introduced the novel idea that “GEFS+ is not always a familial syndrome” (100). Neurologic examination is usually normal. However, individual patients may present neurologic symptoms as part of a given epilepsy syndrome (ie, ataxic gait or action myoclonus in Dravet syndrome). Environment, genetic background, and epigenetic modifications may also have an important role in the disease presentation.

An outline of epileptic syndromes and seizure types that constitute the spectrum of GEFS+ are designated bellow.

Febrile seizures. Febrile seizures are generalized tonic-clonic seizures occurring during fever higher than 38^oC in children ranging from 3 to 6 months to 6-years-old (120; 101). Febrile seizures are the prominent seizure type of GEFS+, with their incidence ranging between 33% to 44% according to different reviews (25; 157).

Febrile seizures usually last a few minutes and resolve spontaneously. They are considered complex when duration is more than 15 minutes, there is more than one episode in 24 hours, and there is the presence of focal seizures. Positive family history for febrile seizures and genetic predisposition are very common in this fever-associated disorder that has an incidence of 3% to 4% in the pediatric population. Outcome is almost always favorable (25).

Febrile seizures plus (FS+). The term febrile seizures plus is defined by the presence of febrile seizures, usually generalized, that occur outside the age limits of between 3 months and 6 years, and/or afebrile generalized tonic-clonic seizures (125; 43). These afebrile generalized tonic-clonic seizures may occur during the classic febrile seizure age range, after febrile seizures remit, or, in rare instances, in late childhood or early adulthood (136; 135; 122).

Febrile seizures plus correspond to a frequent phenotype of GEFS+ syndrome with about 20% of patients fulfilling FS+ criteria; of them, 9% initially presented with simple febrile seizures (157). The prominent feature in this group seems to be the presence of rare generalized tonic-clonic seizures. Oller-Daurella and Oller noted that isolated “grand mal” in childhood frequently started with febrile convulsions and was usually limited to a few seizures (107). Lennox-Buchtal reported that generalized tonic-clonic seizures following febrile convulsions were often nocturnal, infrequent, relatively benign in nature, and with spontaneous remission (76). Nelson and Ellenberg found that 18 (1%) of their patients with afebrile seizures after febrile convulsions had only one or a few seizures, with remission before 48 months of age (103; 104).

Extremely prolonged febrile seizures lasting more than 30 minutes could be classified as febrile seizures plus. In fact, the FEBSTAT cohort study of children with febrile status epilepticus revealed a higher incidence of febrile seizures and epilepsy in families of patients with febrile status epilepticus when compared with patients with simple febrile seizures (46.5% vs. 28.3%) (61). A susceptibility for febrile status epilepticus in GEFS+ patients could thus be implied.

Febrile seizures plus are considered a mild subgroup of GEFS+; patients experience a spontaneous remission and a normal neurodevelopment (101).

Febrile seizures (plus) and other seizure types. The first GEFS+ family described by Scheffer and Berkovic in 1997 included few probands that, apart from febrile seizures, suffered from absences, atonic seizures, and one proband with myoclonic-astatic epilepsy. Absence seizures in GEFS+ have been reported by other authors as well but their patterns are different from the typical childhood absence epilepsy as seizures are infrequent instead of multiple per day (157).

Myoclonic-astatic epilepsy (or Doose syndrome) is an age-specific epileptic syndrome characterized by generalized myoclonic-atonic seizures that often present with drop attacks in preschool-aged children. Other types of generalized seizures (GTCS, absences, atypical absences) may develop at the course of the disease. A family history of febrile seizures is found positive in more than one fourth of patients (71). A synchronous to seizure onset neurodevelopmental regression results in various outcomes ranging from normal to impaired intelligence (05).

Focal seizures. Focal seizures were responsible for approximately 9% of total seizure manifestation in 409 GEFS+ affected individuals (157). Temporal lobe epilepsy may occur following febrile seizures or FS+, either alone or associated with hippocampal sclerosis. The FEBSTAT prospective study demonstrated that children with febrile status epilepticus have increased risk for developing acute hippocampal injury (133). Frontal lobe epilepsy has been described in GEFS+ families presenting with hemiclonic seizures and orofacial motor seizures (12; 11; 122).

Occipital lobe epilepsy and Panayiotopoulos syndrome have been described in GEFS+ families as phenotypes not generally recognized within the GEFS+ spectrum (45). Four individuals with Panayiotopoulos syndrome in a SCN1A mutation positive GEFS+ family were also reported by Kivity and colleagues (72). The above data led to include epilepsy with centrotemporal spikes in GEFS+ focal epilepsies, but no more cases have been reported to our knowledge in the literature in order to confirm more than a chance association (45).

The spectrum of GEFS+ has been enriched by epilepsy with auditory features. Bisulli and colleagues described a mother and a daughter with prominent auditory ictal manifestations that belonged to a family where eight members had a GEFS+ typical phenotype (16). A missense pathogenic mutation in the SCN1A gene was detected. In another GEFS+ four-generation family with SCN1A mutation and nine affected subjects, the electroclinical features indicated a temporal-parietal-occipital carrefour epilepsy (116).

Dravet syndrome. Dravet syndrome is associated with the most severe form of GEFS+ phenotype. This distinctive genetic syndrome is associated with different types of drug-resistant seizures that appear during the first year of life. Dravet syndrome patients demonstrate a susceptibility to febrile seizures and status epilepticus; cognitive and motor decline appear soon after seizure onset in a previously normal developing child. Dravet syndrome represents the most typical single-gene (SCN1A) associated epilepsy, with an incidence estimated at 1 in 15,500 (141).

Veggiotti and colleagues first reported the cases of two brothers diagnosed with Dravet syndrome who belonged to a family of GEFS+ and suggested that Dravet syndrome might be the most severe end of the GEFS+ spectrum (145). Singh and colleagues found a high incidence of a family history of febrile seizures in the families of 12 patients with Dravet syndrome and reached a similar conclusion (136). To illustrate the phenotypic variability, Grant and Vasquez reported on a 10-year-old boy, with normal early development, who experienced febrile seizures at two years of age and later experienced multiple types of seizures (afebrile myoclonic seizures, spasms, and absences) (51). A family history of simple febrile seizures was noted. EEG and MRI were all normal at onset, and video-EEG performed at the age of 4 years and 8 months demonstrated interictal and ictal abnormalities. The child also presented behavioral difficulties and, during the second decade, presented with difficult-to-control afebrile generalized seizures. The patient was considered to have a moderate phenotype within the GEFS+ spectrum relative to myoclonic-astatic epilepsy or benign myoclonic epilepsy of infancy.

Although the SCN1A gene has been correlated with less severe GEFS+ phenotypes, data suggest that patients with SCN1A de novo or inherited heterozygous mutations present in around 80% with severe Dravet syndrome clinical spectrum (141).

More than 1800 mutations have been identified in SCN1A (39). A prediction model for early diagnosis of SCN1A-related epilepsies has been proposed by Brunklaus and colleagues in 2022 (22). This model will tend to accurately discriminate patients that will develop Dravet syndrome versus other GEFS+ phenotypes. This prediction model could allow an objective estimation at disease onset of which a child will develop Dravet syndrome versus GEFS+, assisting clinicians with prognostic counseling and helping to take decisions on early use of precision therapies (22).

Prognosis and complications

Although the overall phenotype of GEFS+ families tends to be mild (several members will only have febrile seizures, FS+, or rare GTCS that will remit until early adolescence), prognosis can only be discussed for individuals. Therefore, the syndromic diagnosis for each affected member must be considered separately.

Regarding the overall spectrum of clinical features associated with GEFS+, the most severe end of the spectrum is represented by Dravet syndrome with its poor prognosis and the least severe end by febrile non-recurrent convulsions. Patients with Dravet syndrome appear to be susceptible to frequent seizures or status epilepticus (24).

Genetic epilepsy with febrile seizures plus may be complicated by sudden unexpected death in epilepsy (SUDEP). Myers and colleagues described two GEFS+ families in which at least one individual had suffered a SUDEP, according to the Epilepsy Pharmacogenomics Research Database. The first individual was a 22-month-old girl who was carrying a pathogenic SCN1B variant and presented with a FS+ phenotype. In the second family, the elder of two brothers with atypical multifocal SCN1A-associated Dravet syndrome died suddenly at the age of seven years after status epilepticus (102). Status epilepticus and SUDEP have a high incidence of Dravet syndrome; more data are needed to confirm their relationship with milder GEFS+1 phenotype, given the association of the SCN1B mutation with Brugada and long QT syndrome.

Data regarding outcomes and comorbidities in SCN1A-related GEFS+ have become available (29). In a Dutch cohort of 164 patients, walking disabilities and severe behavioral problems affect 71% and 43% of patients with Dravet syndrome respectively, whereas only mild learning problems and psychological/behavioral problems are reported for 27% and 38% respectively non-Dravet syndrome patients. Eighty-five percent/majority of patients with non-Dravet syndrome become seizure-free at 10 years follow-up.

Clinical vignette

A 7-year-old male patient was referred for consultation after a generalized tonic-clonic seizure of short duration. The boy had experienced febrile seizures twice during his second year of life on the occasion of viral upper respiratory infections; no investigation was proposed. He had an otherwise unremarkable perinatal and medical history. Neurodevelopment was appropriate for age and neurologic examination was strictly normal at referral. A few weeks after the appointment, he had another episode of febrile seizures. Standard scalp EEG showed generalized spike-wave activity. A brain MRI was normal. He had an older sister with a history of two febrile convulsions by the age of three years, followed by epileptic episodes of head-nodding and rare falls (orienting to a syndromic diagnosis of myoclonic-atonic epilepsy). Both brother and sister responded relatively well to valproate, but the sister had to remain under treatment until the age of 11 years. Seizure freedom and normal psychomotor development at the age of 12 years was achieved for both siblings.

Extensive history taking revealed that the father had also experienced febrile seizures until the age of eight years and that one of his uncles was considered to be epileptic at a young age, but detailed data were not available.

Different individuals of this family have presented with heterogenous clinical manifestations (FS+ in the father, GTCS, and other seizure types in the others), orientating the diagnosis to GEFS+ and the performance of genetic testing.

Biological basis

Etiology and pathogenesis

GEFS+ has great genetic and phenotypic variability. The various types of seizures or epilepsy syndromes are transmitted by autosomal dominant inheritance with incomplete penetrance, but recessive inheritance, de novo, and mosaic cases have also been identified (21; 100). However, the genetic cause is until today identified in a minority of families. In a study of 60 GEFS+ families with 409 affected individuals, only one third of the tested families (50/163) had a pathogenic variant in a GEFS+ known gene (157). The majority of genes identified so far include sodium channels and GABA-A receptors, suggesting that this “genetic syndrome” belongs to the “channelopathies.” The possible pathophysiological role of identified genes associated with GEFS+ is discussed in detail in the following section.

SCN1B gene (GEFS+ type 1). The first locus for the GEFS+ spectrum was mapped to chromosome 19q13 (150), where the voltage-gated sodium channel beta1 subunit gene (SCN1B) was subsequently identified. Grinton and colleagues reported in their study that the SCN1B gene pathogenic variants account for approximately 8% of GEFS+-affected families. Penetrance of SCN1B variants has been estimated at 62% to 76%.

A missense mutation of this gene (C121W) was found in two unrelated families (150; 149). In heterozygotes, association between inactive beta subunits and alpha subunits would generate a persistent sodium current rendering neurons hyperexcitable and apt to initiate firing under small depolarizations (92). Whole-cell voltage clamp experiments using Chinese hamster ovary cells found increased neuronal excitability induced by the C121W mutation (44). Further in vivo rodent models led to the hypothesis that SCN1B-C121W confers a deleterious gain-of-function mutation in GEFS+ patients (73).

A second mutation was identified in a Belgian family, the p.170_E74del (06). Two further mutations (R85C and R85H) have also been identified in two families (123). They could increase neuronal excitability and underlie GEFS+ pathogenesis (154). Brackenbury and colleagues suggested that SCN1B is critical for neuronal proliferation, migration, and pathfinding during the critical postnatal period of brain development (20). They described an abnormal neuronal patterning, which occurred during early postnatal brain development in SCN1B-null mice and preceded hyperexcitability. A crystallographic analysis established that the β1 gene mutations associated with GEFS+ impaired the β1-mediated cell-cell adhesion, and this should underlie the GEFS+ pathogenesis (132).

The pathophysiological mechanism of the p.Asp25Asn (D25N; c.73G> A) mutation of the β1 subunit reported in a patient with GEFS+ was investigated by Baroni and colleagues (09). It causes a maturation (glycosylation) defect of the protein and disables its interaction with the α subunit.

Missense novel biallelic variants of the SCN1B gene in homozygous condition have also been reported in two siblings with febrile plus seizures, one of them mimicking Dravet syndrome (27). This c.265C>T variant predicting p.Arg89Cys is located in the extracellular immunoglobulin loop domain of the protein, which mediates interaction of the beta‐1 subunit with cellular adhesion molecules (27). It was thus considered pathogenic, expanding the spectrum of recessive inheritance in GEFS+. At the same time, an analysis of 22 Dravet syndrome patients without SCN1A variants has identified only two exon SCN1B variants (c.351C> T, p.G117G, and c.467C> T, p.T156M) in very low frequencies, thus doubting the causative connection of heterozygous SCN1B mutations with Dravet syndrome (50).

To conclude, a review by Zhu and colleagues (159) identified 20 families and 6 individuals (including the index case described herein) reported to have SCN1B-related epilepsy, and authors concluded that individuals with monoallelic pathogenic variants in SCN1B often present with genetic epilepsy with febrile seizures plus (GEFS+), whereas those with biallelic pathogenic variants may present with developmental and epileptic encephalopathy (DEE) (159).

SCN1A gene (GEFS+2). It is estimated that the most frequent mutations found in GEFS+ families are within the SCN1A gene, accounting for 5.6% of the cases in large series, 10% to 11.5% in other reports, and 20% in more recent estimations (89; 155; 124). Two GEFS+ families with linkage to chromosome 2q24-33 were reported (47). One mutation (R1648H) accelerated the recovery from inactivation, with consequent neuronal hyperexcitability (69). To understand how other GEFS+ causing SCN1A mutations affect neural circuits and behaviors, Das and colleagues established a second knock-in mouse model using CRISPR/Cas9 editing (28). The K1270T mice represent an important tool for identifying similarities and differences in mechanism of action with R1648H and other mutations (28). Electrophysiological studies of human SCN1A with the mutations T875M, R1648H, or W1204R in a mammalian expression system (46), suggest these mutations confer a gain of function that may be responsible for symptoms associated with GEFS+ (83). Moreover, the mutations I1656M and R1657C were consistently associated with a loss of function (82) and mutations V1353L and A1685V with a complete abrogation of sodium channel activity. A novel SCN1A missense mutation in exon 21 (p.K1372E) was identified in 17 individuals in an Ashkenazi Jewish family with important phenotypic heterogeneity, from unaffected carriers to Dravet syndrome (49). Another example of remarkable clinical heterogeneity among family members was given by Passamonti and colleagues in a 3-generation Italian family carrying the c.2946+5G>A splicing mutation (108). Moretti and colleagues described two additional families in which affected individuals had biallelic SCN1A variants (96). Both patients (one per family, from related parents in each case) had fever-sensitive epilepsy beginning in the first months of life, followed by afebrile seizures and without severe cognitive impairment. Other authors have reported two siblings from a consanguineous pedigree with epilepsy phenotype compatible with GEFS+ associated with a homozygous likely pathogenic SCN1A variant (87). These two patients were compared to 10 previously published with epilepsy and variants in compound heterozygosity or homozygosity in the SCN1A gene. A case of two missense mutations in cis (p.[Arg1525Gln; Thr297Ile]) in all affected individuals of an Italian family showing GEFS+ and idiopathic generalized epilepsy features is also reported (15). Functional studies of the novel p.Arg1525Gln mutation in association with a previously known SCN1A cis mutation revealed significant shift in the activation curve towards more positive potentials of Nav1.1 channels (15).

Mutational analysis of SCN1A in patients with Dravet syndrome has revealed a high frequency (70%) of mutations, which are shown to be dominant and occur de novo as sporadic cases. In a series of 333 patients with Dravet syndrome, all possible types of mutations were identified along the length of the SCN1A gene; missense mutations were the most common (36). SCN1A truncation mutations thus far appear to be exclusive to Dravet syndrome; however, one report identified a novel de novo splice-site mutation within the SCN1A gene, which led to a protein truncation in a patient with focal epilepsy and FS+ (74). A subsequent mutation was identified in a patient with a milder FS+ phenotype (66). The preferred mechanism to explain the effect of the wide spectrum of mutations is haploinsufficiency, ie, total loss of function of the mutated allele (36). There are attempts to elucidate mechanisms concerning how missense mutations might influence clinical phenotype in Dravet syndrome and GEFS+. Volkers and colleagues performed a biophysical analysis of three SCN1A missense mutations (R865G, R946C, and R946H), which they detected in six patients with Dravet syndrome, and compared the functionality of the R865G mutation with that of a R859H mutation detected in a GEFS+ patient. The two mutations reside in the same voltage sensor domain of Na(v) 1.1. Their results suggest that the R859H mutation causes GEFS+ as a result of different biophysical defects in Na(v) 1.1 gating (146). Sugiura and colleagues reported two missense mutants at the same residue provoking different degrees of loss of function between GEFS+ and Dravet syndrome (139).

Approximately 10% of patients with Dravet syndrome have SCN1A mutations that are inherited. Furthermore, Depienne and colleagues reported that inherited SCN1A mutations were highly associated with mosaicism (32; 35).

Myers and colleagues reported seven patients with GEFS+ phenotypes with de novo SCN1A pathogenic variants, including a pair of monozygotic twins, that caused milder phenotypes (100). Four pathogenic variants were located in the pore-forming regions of SCN1A, one in the N-terminal and one in the voltage sensor region. They came to the paradoxical conclusion that GEFS+ is not necessarily inherited or familial because it can present in sporadic individuals, and as such, family history is not essential for its diagnosis (100).

A practical reference guide for the genetic testing of SCN1A in epilepsy has been published (63). More than 1200 mutations to date have been identified in the SCN1A gene, and the list is continuously growing, with targeted population-based sequencing of the gene in patients with Dravet syndrome and GEFS+ (111; 144).

GABRG2 gene (GEFS+ 3). The GABA-A receptor gamma2 subunit gene, GABRG2 (5q34), is also reported to be involved in the pathogenesis of GEFS+ (13; 147). Eight mutations have been identified so far, of which six were identified in GEFS+ families: R43Q, R139G, K289M, P83S, the c.1329delC frameshift mutation, and p.R136* (13; 147a; 08; 75; 142; 68; 17; 59). The mutation p.R136* was discovered in a family with five epileptic members, three of them with history of febrile seizures. The mutation segregated with the febrile seizure component of this family and was also present in an asymptomatic infant (68). A mutation (Q359X) was also identified in a family where the proband had Dravet syndrome (55).

Pathophysiologic mechanisms concerning mutations of the GABRG2 gene are beginning to be elucidated (64; 65). Bouthour and colleagues showed that on raising temperature, both the number of GABA(A) receptor clusters and the frequency of miniature inhibitory postsynaptic currents decreased in neurons expressing the K289M mutation (19). Raising temperature also increased the membrane diffusion of synaptic GABA(A) receptors. The authors concluded that the K289M mutation confers an enhanced sensitivity to neuronal activity and that hyperthermia may then trigger the escape of receptors from synapses and, thereby, further reduce the efficacy of GABAergic inhibition. For the missense mutation R43Q of the same gene, a lower temperature threshold for thermal seizures was displayed in mice (62). For another mutation, Q351X, mutant γ2(Q351X) subunits were shown to be degraded more slowly than wild-type gamma2 subunits and formed aggregates within rat cortical neurons (70). Another group showed a significant change in the expression of several epilepsy-related genes in a GABRG2 gene knockout cell-line (HT22GABRG2KO) model of HT-22 mouse hippocampal neuronal cells (78). Hernandez and colleagues characterized the effects of eight variants in the GABAA receptor 2 subunit on receptor biogenesis and channel function (one from a GEFS+ family) (59). Their data supported the link between febrile seizures, epilepsy, and GABRG2 variants, shedding light on the relationship between the variant topological occurrence and disease severity by employing a combination of genetic, structural, and functional in vitro assays.

GABRD gene (GEFS+5). GABRD, which encodes the delta subunit of GABA-A receptor, is a putative susceptibility gene for GEFS+. Mutations in this gene were identified in a family of siblings with FS+ and febrile seizures (37). In vitro studies demonstrated that expression of the GABRD mutation, E177A, in human embryonic kidney cells produced "markedly reduced current when exposed to a saturating concentration of GABA” (122).

GABRB3 gene. GABRB3 encodes for the beta3 subunit of the GABAA receptor, GABRB3 mutations cause reduced receptor function, predicting impairment of GABA-mediated inhibition, and it has been associated with severe epilepsies. In a large cohort of 416 patients with various epilepsies, 22 patients were found to have presumed pathogenic variants in GABRB3. Fourteen were de novo mutations; three mutations segregated in the family in a dominant fashion, one was inherited from the asymptomatic mother who was mosaic for the mutation, and two were inherited from an unaffected parent (95). The phenotype described is quite wide, including FS, early-onset absence epilepsy, myoclonic atonic epilepsy, unclassified focal epilepsies, Dravet syndrome like, West syndrome, Lennox-Gastaut syndrome, and other epileptic encephalopathies.

Other genes and genetic aspects to consider.

SCN9A gene (GEFS+7). Singh and colleagues identified mutations in the SCN9A gene in patients with Dravet syndrome as well as simple febrile seizures, self-limited afebrile seizures, and temporal lobe epilepsy (134). Another study reported that SCN9A susceptibility variants may contribute to complex inheritance for cases of Dravet syndrome without SCN1A mutations (99). Subsequent reports further support the association of monogenic SCN9A mutations and GEFS+ spectrum (157; 03; 158).

STX1B gene (GEFS+9) and synaptopathies. Schubert and colleagues reported the identification of mutations in STX1B encoding syntaxin-1B6 that are associated with both febrile seizures and epilepsy (127). First the authors presented data from two large pedigrees previously reported with linkage to chromosome 16p11.2 and 16p12-q12 (77; 151). Then three more mutations were identified in 449 familial or sporadic cases, and analyses of zebrafish larvae showed seizure-like behavior and epileptiform discharges that were highly sensitive to increased temperature. Two missense mutations resulted in nonconservative amino acid substitutions within the highly conserved SNARE motif region of STX1B. The authors propose this class of mutations as “synaptopathies.”

An article reported three affected members of a GEFS+ Chinese family carrying a novel heterozygous mutation of c.705 locus of STX1B (143). The same team attempted a literature review with a total of 10 mutations of the STX1B gene (half of them missense mutations) in 36 patients with GEFS+ phenotype, further supporting the association of the locus with this genetic syndrome (143). The convergence of mutations in genes encoding the synaptic vesicle release machinery suggests that this is a significant pathogenic pathway. Haag and colleagues succeeded the generation of an induced pluripotent stem cell (iPSC) line from a patient with GEFS+ carrying a STX1B mutation (53).

HCN1 (GEFS+10). Hyperpolarization-activated cyclic nucleotide-gated channels control neuronal excitability and few mutations reported so far in their encoding genes have been linked to epileptic encephalopathies. In a cohort of 33 patients with novel pathogenic or likely pathogenic variants, 36% of the patients had the first during a febrile illness whereas the GEFS+ spectrum was in total amongst the most predominant phenotypes (90). The authors also conducted further genotype and functional analysis suggesting that more severe phenotypes were related with variants within or close to transmembrane domains of the channel; different variants result to a wide biochemical alteration ranging from complete loss-of-function to important changes in activation kinetics and/or voltage dependence (90). The role of HCN1 mutations in GEFS+ pathogenesis needs further investigation.

SCN2A gene. A missense mutation encoding the alpha-subunit of neuronal voltage-gated Na(+) channel type II (Na(v)1.2) in a patient with febrile seizures associated with afebrile seizures was first reported by Sugawara and colleagues in 2001 (138). Experimental models showed that R188W mutation-related neuronal hyperexcitability was correlated with slower inactivation of the mutant channel than wild-type resulting in augmented Na (+) influx, whereas the Na(+) channel conductance was not affected (138).

Possible causative role of the SCN2A gene in GEFS+ is further supported by the report of a heterozygous mutation c.1399G>A on exon11 of SCN2A (Nav1.2) in a twin family with GEFS+ (81). A study among Egyptian children established an association between SCN2A c. 56 G/A genetic polymorphism (SCN2A rs17183814) and febrile seizure plus (14). This study also showed that carriers of this SCN2A polymorphism tended to respond poorly to antiepileptic drugs.

Copy number variations. Hartmann and colleagues performed a genome-wide screening for copy number variations (CNVs) in 36 patients with SCN1A-negative fever-associated syndromic epilepsies (56). Phenotypes included Dravet syndrome (n=23; 64%), GEFS+/FS+ (n=11; 31%), and unclassified fever-associated epilepsies (n=2; 6%). They identified 13 rare CNVs in 8 out of 36 (22%) individuals. These included known pathogenic CNVs in 4 of 36 (11%) patients: a 1q21.1 duplication in a proband with Dravet syndrome, a 14q23.3 deletion in a proband with FS+, and two deletions at 16p11.2 and 1q44 in two individuals with fever-associated epilepsy with concomitant autism and/or intellectual disability. Three additional CNVs were classified as likely pathogenic and six CNVs were of unknown significance. They suggested that fever-associated epilepsy syndromes may be a recurrent clinical presentation of known microdeletion syndromes.

Fortin and colleagues reported an overrepresentation of CNVs in their small cohort of chromosomal microarray analysis in 12 GEFS+ families (48). Four of the twelve families had at least one copy number CNV identified (15q11.2 deletion, 19p13.3 deletion affecting CACNA1A, 10q11.22 duplication, and 22q11.2 deletion).

PRRT2 gene. The proline-rich transmembrane protein 2 (PRRT2) gene was identified to be related to paroxysmal kinesigenic dyskinesia, and infantile convulsions with paroxysmal kinesigenic dyskinesia, but He and colleagues screened PRRT2 exons in a cohort of 136 epileptic patients with febrile seizures including FS+, GEFS+, and Dravet syndrome (58). PRRT2 genetic mutations were identified in 25 out of 136 (18.4%). Five loss-of-function and coding missense mutations were identified.

CHRNA4 gene. CHRNA4 encodes for the alpha4 subunit of the neuronal nicotinic acetylcholine receptor, and it was identified in three individuals with episodic dyskinesia and febrile seizures that were PRRT2-negative (67).

SLC32A1 gene. An important genetic study by Heron and colleagues identified previously unreported missense variants in SLC32A1 gene (60). For the scope of the study, whole genome sequencing data from 1165 epilepsy patients from the Epi4K dataset and 1329 Australian patients from the Epi25 dataset were interrogated. Two variants cosegregated with the phenotype in two large GEFS+ families with 8 and 10 affected subjects. Six further variants were identified in smaller families with GEFS+ or idiopathic generalized epilepsy (60). These variants are predicted to alter GABA transport into synaptic vesicles, leading to altered neuronal inhibition.

Other genes. Other genes associated with a small subset of patients with Dravet syndrome include SCN1B (109), SCN2A (130), and PCDH19 (33; 88). The PCDH19 gene encodes protocadherin 19 and is believed to play a major role in epileptic encephalopathies (previously implicated in epilepsy and mental retardation limited to females) (38). In a study by Depienne and colleagues, 150 unrelated patients (113 females) with febrile and afebrile seizures were screened for PCDH19 mutations (34). Mutations were identified in 18 patients with highly variable clinical features but almost always included a high sensitivity to fever and clusters of brief seizures. The familial condition was suggestive of GEFS+ in a family, with three affected females presenting with partial cryptogenic epilepsy. Thus, this X-linked gene appears to mainly affect females, and the presence of an affected mosaic male indicates that cellular interference is at least one pathogenic mechanism (33). Another example of maternal transmission in a GEFS+ family was a report of a balanced translocation between chromosome X and 14 in which the breakpoint on the X chromosome disrupted a gene that encodes an auxiliary protein of voltage-gated Na channels, fibroblast growth factor 13 (FGF13) (114). Rigbye and colleagues further investigated whether the mutation of FGF13 would explain other cases of GEFS+ compatible with X-linked inheritance (115). They screened the coding and splice site regions of the FGF13 gene in a sample of 45 unrelated probands in which GEFS+ segregated in an X-linked pattern. The authors subsequently identified a de novo FGF13 missense variant in an additional patient with febrile seizures and facial edema. Their data suggest FGF13 is not a common cause of GEFS+.

Despite all the advances in GEFS+ genetics, reported mutation frequencies of known GEFS+ related genes vary between different series. For example, of the three genes SCN1A, SCN1B, and GABRG2, only a single mutation in SCN1A was identified in a study of 19 GEFS+ Scandinavian families (128), and no mutations were identified in any of the genes in a study of seven GEFS+ Italian families (18) and two GEFS+ Tunisian families (98). In the latter study, an insertion of a T nucleotide within intron 12 of the SCN1A gene was found in two probands and both parents, but it remains unclear whether this is a pathogenic mutation or a polymorphism. In a study of another eight GEFS+ Italian families with mutation screenings of the same genes, mutations were found in two families in the SCN1A gene (113). In a study of 23 GEFS+ Chinese families, SCN1A and GABRG2 mutations were both observed in two of the patients, but no SCN1B mutations were identified (140). A study concerning another three GEFS+ Chinese families did not find any mutations in the four genes, SCN1A, SCN1B, GABRG2, and SCN2A, but results showed a 6 cM candidate interval at 5q33-34 in one family (79). Sequencing candidate genes GABRG2 and GABRA1 in this region did not identify a causative mutation. The c.363C>G (p.Cys121Trp) SCN1B variant has been associated with GEFS+, in at least six independent, multigenerational families (52). This study provides evidence of a single founder event giving rise to the SCN1B c.363C>G variant in 14 independent families with epilepsy. A common haplotype was observed in all families, and the age of the most recent common ancestor was estimated to be approximately 800 years ago. Advances in genetics (next-generation/whole exome sequencing) will provide further insights in the genetic landscape of GEFS+, as implied by the discovery of an H258R mutation in the KCNAB3 gene in a Chinese family with GEFS+ (40). The same authors sought to examine the effects of this KCNAB3 mutation on the potassium channels in mutant mice that they generated and found a decreased total potassium current, suggesting that the KCNAB3 mutation reduced hippocampal potassium currents in this mouse model (41).

Genetic heterogeneity and modifier genes. As stated by Scheffer and Berkovic, the most likely explanation for the phenotypic variability in GEFS+ is an effect of other modifier genes (120; 93). A study to investigate modifier genes in patients with Dravet syndrome who already harbor SCN1A mutations identified mutations in the CACNB4 gene, which encodes for the calcium channel beta-4 subunit (106). Hawkins and colleagues demonstrated that variants in SCN2A, KCNQ2, and SCN8A influence the phenotype of mice carrying the SCN1A R1648H mutation and suggested that ion channel variants may contribute to the clinical variation seen in patients with GEFS+ (57). A few years later, Makinson and colleagues showed that mice with SCN8A reduced expression had seizure resistance, reduced susceptibility to epileptiform activity, reduced hippocampal network excitability, and extended life (85). To further investigate the complex interference of different sodium voted gate channels in epilepsy, Makinson and colleagues introduced the SCN1A-R1648H mutation, identified in a family with GEFS+, into the corresponding position (R1627H) of the mouse SCN8A gene (84). Heterozygous R1627H mice exhibited increased resistance to some forms of pharmacologically and electrically induced seizures, and the mutant SCN8A allele ameliorated the phenotype of SCN1A-R1648H mutants. Paradoxically, at the homozygous level, R1627H mice did not display increased seizure resistance and were susceptible to audiogenic seizures. The authors also observed increased hippocampal pyramidal cell excitability in heterozygous and homozygous SCN8A-R1627H mutants, and decreased interneuron excitability in heterozygous SCN8A-R1627H mutants. These results demonstrate that the effects of a mutation may not be the same in two different voltage gated sodium channels and that targeting the SCN8A gene could on the one hand confer seizure protection but on the other hand increase seizure susceptibility (84).

Mechanistic insight in GEFS+ can be achieved by in vitro and in vivo experimental models.

Murine models have demonstrated that a loss of function of Na(V)1.1 channel (SCN1A) causes refractory seizures and ataxia (156; 105) and have furthermore demonstrated the significance of the genetic background in determining phenotype as heterozygote mice present different characteristics according to different strains (156). This was confirmed in Dravet syndrome mice in pure 129/SvJ genetic background that have fewer seizures with a higher threshold for thermally induced seizures and normal cognitive function compared to mice with an identical mutation but in a C57BL/6J background. It seems that the genetic background is enough to drastically alter the epileptic phenotype, as clinically evidenced in GEFS+ and Dravet syndrome (117).

Data on the SCN1A gene using novel technologies [ie, induced pluripotent stem cell (iPSC) technology] further support NaV1.1 loss-of-function and the hypoexcitability of GABAergic neurons as the main mechanisms related to seizures, at the same time exploring the gene’s mechanistic complexity related to technical issues and to pathophysiologic remodeling (86). However, the genotypic-phenotypic correlation remains challenging as only a few SCN1A variants have been functionally assessed. Brunklaus and colleagues showed that electrophysiological data from mammalian expression systems successfully predicted disease severities. Milder phenotypes retained a degree of channel function measured as residual whole-cell current, whereas the Dravet syndrome phenotype often showed no whole-cell current (23). Xie and colleagues generated two pairs (GEFS+ patient line from two different individuals with the K1270T SCN1A mutation and their controls) of isogenic human iPSC lines by CRISPR-Cas9 gene editing and compared their electrophysiological properties in inhibitory and excitatory iPSC-derived neurons (153). They found that the K1270T mutation causes cell type-specific alterations in sodium current density and evoked firing but also that there are interactions between the mutation and the genetic background. These studies provide encouraging results for potential SCN1A-related disease biomarkers and patient-specific antiseizure therapies.

GEFS+ and inflammation. Genetic epilepsy with febrile seizures plus (GEFS+) is generally considered an ion channelopathy. To date, there have been few studies on inflammation. Choi and colleagues investigated the possible implication of inflammation in the pathogenetic mechanism of febrile seizures and GEFS+ (26). In their study, postictal serum cytokine levels and genetic variants in the cytokine genes interleukin (IL)-1β, IL-6, and high mobility group box-1 of 100 Korean children diagnosed with febrile seizures or GEFS+ were analyzed and compared to controls. Genetic variants located in IL-1β-31 and IL-1β-511 promotor regions were correlated with higher postictal IL-1β levels in febrile seizures, implementing that these variants may represent a host genetic factor for provoking febrile seizures.

In 2022, Ling and colleagues measured the expression level of relevant immune factors such as interleukin-6 (IL-6) in peripheral blood of GEFS+ mice (80). They found out that (CD4+/CD8+) ratio in the GEFS+ mice was decreased, whereas the signal transducer and activator of transcription 3 (STAT3) was activated, and the IL-6 was upregulated. They stated that they expect to provide a theoretical basis for immunosuppressive therapy of GEFS+ and a new way for its clinical treatment.

Differential diagnosis

GEFS+ is a term used to refer to a number of different epileptic seizures and epilepsy syndromes present in the same family. The presence of FS+ in more than one family member may be considered as a distinguishing feature of GEFS+. When dealing with an individual patient with no family history of seizures, a diagnosis other than common febrile seizures is rather impossible.

At the initial evaluation, differential diagnosis should be done (as in all epileptic patients) from symptomatic seizures following acute brain injury, CNS infection, neoplasia, etc. Subsequently, treatable inherited metabolic epilepsies (pyridoxine-dependent epilepsy, Glut-1 transporter deficiency, etc.) should be differentiated based on clinical and EEG phenotype (05).

Weber and colleagues reported a high rate of febrile seizures in a 4-generation family with benign familial infantile seizures (and linkage to the major benign familial infantile seizures locus on chromosome 16) (151); this is an association previously not described and demonstrates overlap between GEFS+ and benign familial infantile seizures. Moreover, mutations in the SCN2A gene are also associated with benign familial neonatal infantile seizures (BFNIS), GEFS+, Dravet syndrome, and some intractable childhood epilepsies (131).

Similarly, in individual patients, differential diagnosis from Dravet syndrome may be difficult. The syndrome usually manifests with unilateral febrile convulsions. The accompanying symptoms (frequent generalized, unilateral or focal seizures precipitated by fever, myoclonic phenomena, EEG abnormalities) are usually not present at onset. Dravet syndrome can be considered as part of the GEFS+ spectrum when other family members fulfill the general criteria described above.

Associated or underlying disorders

In one prospective case-control study by Sager and colleagues, patients with GEFS+ have demonstrated a significantly high impairment in both articulation and auditory discrimination of phonemes compared with healthy individuals (118). The authors conclude that early diagnosis and treatment of this condition could prevent potential problems as the development of dyslexia in the future. However, in this study, the individual genetic causes of GEFS+ patients have not been mentioned.

Management

GEFS+ is an epilepsy syndrome under the latest classification of the ILAE (160), but no global management has been suggested. Individual patients should be treated according to their specific type of epilepsy or type of seizures.

Thus, for patients who have simple or complex febrile seizures, a treatment may not be necessary as the severity of the adverse effects of antiepileptic treatment could outweigh the benefits they may produce (91). However, careful instructions for rescue medication use should be carefully given. According to the FEBSTAT study only 23% of febrile seizures patients with a subsequent febrile seizure lasting more than 10 minutes were administered rectal diazepam (61).

Patients presenting with FS+, an antiepileptic drug, usually with a wide spectrum of applications, is administered--the choice being totally empirical.

For Dravet syndrome, for example, there was an international consensus for use of valproic acid as first-line therapy, and for use of clobazam, fenfluramine, or stiripentol as first-or second-line therapy. There was also consensus for contraindicated medications (sodium channel blocker including lamotrigine). Phenytoin may be helpful for status epilepticus. Other management includes vagal nerve stimulation, levetiracetam, zonisamide, bromides, clonazepam, and ethosuximide (for absences) (152).

Associated seizures will necessitate treatment on the basis of general clinical experience to avoid inappropriate drug choices for specific seizure types (110; 04; 05).

Vagus nerve stimulation was used in a girl with GEFS+ who presented with GTCS and focal seizures with loss of consciousness with over 75% and 80% reduction respectively four years after vagus nerve stimulation initiation, but more studies are needed to confirm its effectiveness and tolerance (54). Effectiveness beyond the Dravet syndrome spectrum needs also to be established for ketogenic diet in GEFS+.

Surgery should be considered as a possible treatment in cases with focal seizures. On the one hand, there are reports of individuals from GEFS+ families with temporal lobe epilepsy that become seizure-free after temporal lobectomy (123). On the other hand, Skjei and colleagues reported on six patients who underwent epilepsy surgery for intractable focal seizures (complete or partial frontal lobectomies or resection on frontoparietal region) (137). All patients were eventually found to have SCN1A mutations, and seizures continued despite surgery. Surgical histopathology showed evidence of subtle cortical dysplasia in four of six patients. More data are thus needed on epilepsy surgery’s efficacy in GEFS+.

An emergency seizure plan written and extensively explained to the family should be provided to all GEFS+ families. Protective helmets for patients experiencing frequent drop attacks should be prescribed. Neurologic and neuropsychological surveillance is essential for optimal outcome. Occupational therapy should be offered to appropriate cases. Vaccination management depends on personal, family, and genetic background. Individualized approaches should be considered (31). Deng and colleagues described an asymptomatic female child with a novel SCN1A variant (31). Her brother who had the same variant died from hypoxic ischemic encephalopathy following his 12-month vaccinations in the context of status epilepticus and enterovirus 71 infection. The index case received vaccination with prophylactic regular sodium valproate and clobazam post vaccination. This case indicates a potential new direction in personalized medicine.

References

01: Abou-Khalil B, Ge Q, Delai R, et al. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology 2001;57:2265-72. PMID 11756608
02: Aicardi J. Epilepsies with generalized tonic-clonic seizures. In: Aicardi J, editor. Epilepsy in Children. 2nd ed. New York: Raven Press 1994:118-29.
03: Alves RM, Uva P, Veiga MF, et al. Novel ANKRD11 gene mutation in an individual with a mild phenotype of KBG syndrome associated to a GEFS+ phenotypic spectrum: a case report. BMC Med Genet 2019;20(1):16. PMID 30642272
04: Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord 2002;4(3):217-25. PMID 12446225
05: Arzimanoglou A, Guerrini R, Aicardi J. Aicardi's epilepsy in children. 3rd edition. Philadelphia, Lippincott Williams & Wilkins; 2004.
06: Audenaert D, Claes L, Ceulemans B, Lofgren A, Van Broeckhoven C, De Jonghe P. A deletion in SCN1B is associated with febrile seizures and early-onset absence epilepsy. Neurology 2003;61(6):854-6. PMID 14504340
07: Audenaert D, Claes L, Claeys KG, et al. A novel susceptibility locus at 2p24 for generalised epilepsy with febrile seizures plus. J Med Genet 2005;42(12):947-52. PMID 15827091
08: Audenaert D, Van Broeckhoven C, De Jonghe P. Genes and loci involved in febrile seizures and related epilepsy syndromes. Hum Mutat 2006;27(5):391-401. PMID 16550559
09: Baroni D, Picco C, Moran O. A mutation of SCN1B associated with GEFS + causes functional and maturation defects of the voltage dependent sodium channel. Hum Mutat 2018;39(10):1402-15. PMID 29992740
10: Baulac S, Gourfinkel-An I, Couarch P, et al. A novel locus for generalized epilepsy with febrile seizures plus in French families. Arch Neurol 2008;65(7):943-51. PMID 18625863
11: Baulac S, Gourfinkel-An I, Nabbout R, et al. Fever, genes, and epilepsy. Lancet Neurol 2004;3(7):421-30. PMID 15207799
12: Baulac S, Gourfinkel-An I, Picard F, et al. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. Am J Hum Genet 1999;65:1078-85. PMID 10486327
13: Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet 2001;28(1):46-8. PMID 11326274
14: Berseem NF, Khattab ESAEH, Saad DS, Abd Elnaby SA. Role of SCN2A c.56G/A gene polymorphism in Egyptian children with genetic epilepsy with febrile seizure plus. CNS Neurol Disord Drug Targets 2022;21(5):450-7. PMID 34607551
15: Binini N, Sancini G, Villa C, et al. Identification of two mutations in cis in the SCN1A gene in a family showing genetic epilepsy with febrile seizures plus (GEFS+) and idiopathic generalized epilepsy (IGE). Brain Res 2017;1677:26-32. PMID 28951233
16: Bisulli F, Lichetta L, Baldassari S, et al. SCN1A mutations in focal epilepsy with auditory features: widening the spectrum of GEFS plus. Epileptic Disord 2019;21(2):185-91. PMID 30977726
17: Boillot M, Morin-Brureau M, Picard F, et al. Novel GABRG2 mutations cause familial febrile seizures. Neurol Genet 2015;1(4):e35. PMID 27066572
18: Bonanni P, Malcarne M, Moro F, et al. Generalized epilepsy with febrile seizures plus (GEFS+): Clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B, and GABRG2 gene mutations. Epilepsia 2004;45:149-58. PMID 14738422
19: Bouthour W, Leroy F, Emmanuelli C, et al. A Human Mutation in Gabrg2 Associated with Generalized Epilepsy Alters the Membrane Dynamics of GABAA Receptors. Cereb Cortex 2012;22(7):1542-53. PMID 21908847
20: Brackenbury WJ, Yuan Y, O’Malley HA, Parent JM, Isom LL. Abnormal neuronal patterning occurs during early postnatal brain development of Scn1b-null mice and precedes hyperexcitability. Proc Natl Acad Sci U S A 2013;110(3):1089-94. PMID 23277545
21: Brunklaus A, Ellis R, Stewart H, et al. Homozygous mutations in the SCN1A gene associated with genetic epilepsy with febrile seizures plus and Dravet syndrome in 2 families. Eur J Paediatr Neurol 2015;19(4):484-8. PMID 25795284
22: Brunklaus A, Pérez-Palma E, Ghanty I, et al. Development and validation of a prediction model for early diagnosis of SCN1A-related epilepsies. Neurology 2022;98(11):e1163-74. PMID 35074891
23: Brunklaus A, Schorge S, Smith AD, et al. SCN1A variants from bench to bedside-improved clinical prediction from functional characterization. Hum Mutat 2020;41(2):363-74.** PMID 31782251
24: Brunklaus A, Zuberi SM. Dravet syndrome--from epileptic encephalopathy to channelopathy. Epilepsia 2014;55(7):979-84. PMID 24836964
25: Camfield P, Camfield C. Febrile seizures and genetic epilepsy with febrile seizures plus (GEFS+). Epileptic Disord 2015;17(2):124-33. PMID 25917466
26: Choi J, Choi SA, Kim SY, et al. Association analysis of interleukin-1β, interleukin-6, and HMGB1 variants with postictal serum cytokine levels in children with febrile seizure and generalized epilepsy with febrile seizure plus. J Clin Neurol 2019;15(4):555-63. PMID 31591845
27: Darras N, Ha TK, Rego S, et al. Developmental and epileptic encephalopathy in two siblings with a novel, homozygous missense variant in SCN1B. Am J Med Genet Part A 2019;179(11):2190-5. PMID 31465153
28: Das A, Zhu B, Xie Y, et al. Interneuron dysfunction in a new mouse model of SCN1A GEFS. eNeuro 2021;8(2):ENEURO.0394-20.2021. PMID 33658306
29: de Lange IM, Gunning B, Sonsma ACM, et al. Outcomes and comorbidities of SCN1A-related seizure disorders. Epilepsy Behav 2019;90:252-9. PMID 30527252
30: Deng H, Zheng W, Song Z. The genetics and molecular biology of fever-associated seizures or epilepsy. Expert Rev Mol Med 2018;20:e3. PMID 29661262
31: Deng L, Ma A, Wood N, Ardern-Holmes S. Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: a case report on a potential new direction in personalised medicine. Seizure 2020;78:49-52. PMID 32193085
32: Depienne C, Arzimanoglou A, Trouillard O, et al. Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy. Hum Mutat 2006;27(4):389. PMID 16541393
33: Depienne C, Bouteiller D, Keren B, et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet 2009b;5(2):e1000381. PMID 19214208
34: Depienne C, Trouillard O, Bouteiller D, et al. Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in females. Hum Mutat 2011;32(1):E1959-75. PMID 21053371
35: Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 2010;47:404-10. PMID 20522430
36: Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009a;46;183-91. PMID 18930999
37: Dibbens LM, Feng HJ, Richards MC, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 2004;13(13):1315-9. PMID 15115768
38: Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008;40(6):776-81. PMID 18469813
39: Ding J, Li X, Tian H, et al. SCN1A mutation-beyond Dravet syndrome: a systematic review and narrative synthesis. Front Neurol 2021;12:743726.** PMID 35002916
40: Ding J, Miao QF, Zhang JW, et al. H258R mutation in KCNAB3 gene in a family with genetic epilepsy and febrile seizures plus. Brain Behav 2020;10(12):e01859. PMID 32990398
41: Ding J, Wang C, Huang GQ, et al. Functional characterization of a KCNAB3 genetic epilepsy with febrile seizures plus adult mouse model. Transl Pediatr 2022;11(10):1615-23. PMID 36345448
42: Ding J, Zhang JW, Guo YX, Zhang YX, Chen ZH, Zhai QX. Novel mutations in SCN9A occurring with fever-associated seizures or epilepsy. Seizure 2019;71:214-8. PMID 31394368
43: Eckhaus J, Lawrence KM, Helbig I, et al. Genetics of febrile seizure subtypes and syndromes: a twin study. Epilepsy Res 2013;105(1-2):103-9. PMID 23522981
44: Egri C, Vilin YY, Ruben PC. A thermoprotective role of the sodium channel β1 subunit is lost with the β1 (C121W) mutation. Epilepsia 2012;53(3):494-505. PMID 22292491
45: Epi4K Consortium. Phenotypic analysis of 303 multiplex families with common epilepsies. Brain 2017;140(8):2144-56. PMID 28899008
46: Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus and prevalence of variants in patients with epilepsy. Am J Hum Genet 2001;68:866-73. PMID 11254445
47: Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal Na+ channel, in two families with GEFS+2. Nat Genet 2000;24(4):343-5. PMID 10742094
48: Fortin O, Vincelette C, Chénier S, et al. Copy number variation in genetic epilepsy with febrile seizures plus. Eur J Paediatr Neurol 2020;27:111-5. PMID 32595013
49: Goldberg-Stern H, Aharoni S, Afawi Z, et al. Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus. J Child Neurol 2014;29(2):221-6. PMID 24257433
50: Gong JE, Liao HM, Long HY, et al. SCN1B and SCN2B gene variants analysis in dravet syndrome patients: analysis of 22 cases. Medicine (Baltimore) 2019;98(13):e14974. PMID 30921204
51: Grant AC, Vasquez B. A case of extended spectrum GEFS+. Epilepsia 2005;46 Suppl 10:39-40. PMID 16359470
52: Grinton BE, Robertson E, Fearnley LG, et al. A founder event causing a dominant childhood epilepsy survives 800 years through weak selective pressure. Am J Hum Genet 2022;109(11):2080-87. PMID 36288729
53: Haag C, Uysal B, Marquetand J, et al. Generation of an induced pluripotent stem cell (iPSC) line from a patient with GEFS+ carrying a STX1B (p.Lys45delinsArgMetCysIleGlu and p.Leu46Met) mutation. Stem Cell Res 2023;67:103028. PMID 36652844
54: Hanaya R, Niantiarno FH, Kashida Y, et al. Vagus nerve stimulation for genetic epilepsy with febrile seizures plus (GEFS+) accompanying seizures with impaired consciousness. Epilepsy Behav Case Rep 2016;7:16-9. PMID 28070485
55: Harkin LA, Bowser DN, Dibbens LM, et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 2002;70(2):530-6. PMID 11748509
56: Hartmann C, von Spiczak S, Suls A, et al. Investigating the genetic basis of fever-associated syndromic epilepsies using copy number variation analysis. Epilepsia 2015;56(3):e26-32. PMID 25690317
57: Hawkins NA, Martin MS, Frankel WN, Kearney JA, Escayg A. Neuronal voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizures plus. Neurobiol Dis 2011;41(3):655-60. PMID 21156207
58: He ZW, Qu J, Zhang Y, et al. PRRT2 mutations are related to febrile seizures in epileptic patients. Int J Mol Sci 2014;15(12):23408-17. PMID 25522171
59: Hernandez CC, Shen Y, Hu N, et al. GABRG2 variants associated with febrile seizures. Biomolecules 2023;13(3):414. PMID 36979350
60: Heron SE, Regan BM, Harris RV, et al. Association of SLC32A1 missense variants with genetic epilepsy with febrile seizures plus. Neurology 2021;96(18):e2251-60. PMID 34038384
61: Hesdorffer DC, Shinnar S, Lax DN, et al. Risk factors for subsequent febrile seizures in the FEBSTAT study. Epilepsia 2016;57(7):1042-7. PMID 27265870
62: Hill EL, Hosie S, Mulligan RS, et al. Temperature elevation increases GABA(A) -mediated cortical inhibition in a mouse model of genetic epilepsy. Epilepsia 2011;52(1):179-84. PMID 21219304
63: Hirose S, Scheffer IE, Marini C, et al. SCN1A testing for epilepsy: application in clinical practice. Epilepsia 2013;54(5):946-52. PMID 23586701
64: Huang X, Hernandez CC, Hu N, Macdonald RL. Three epilepsy-associated GABRG2 missense mutations at the γ+/β- interface disrupt GABAA receptor assembly and trafficking by similar mechanisms but to different extents. Neurobiol Dis 2014;68:167-79. PMID 24798517
65: Ishii A, Kanaumi T, Sohda M, et al. Association of nonsense mutation in GABRG2 with abnormal trafficking of GABAA receptors in severe epilepsy. Epilepsy Res 2014;108(3):420-32. PMID 24480790
66: Jaimes A, Guerrero-López R, González-Giráldez B, Serratosa JM. De novo truncating mutation in SCN1A as a cause of febrile seizures plus (FS+). Epileptic Disord 2020;22(3):323-6. PMID 32540801
67: Jiang YL, Yuan F, Yang Y, Sun XL, Song L, Jiang W. CHRNA4 variant causes paroxysmal kinesigenic dyskinesia and genetic epilepsy with febrile seizures plus? Seizure 2018;56:88-91. PMID 29454195
68: Johnston AJ, Kang JQ, Shen W, et al. A novel GABRG2 mutation, p.R136, in a family with GEFS+ and extended phenotypes. Neurobiol Dis 2014;64:131-41. PMID 24407264
69: Kahlig KM, Misra SN, George AL Jr. Impaired inactivation gate stabilization predicts increased persistent current for an epilepsy-associated SCN1A mutation. J Neurosci 2006;26(43):10958-66. PMID 17065438
70: Kang JQ, Shen W, Lee M, Gallagher MJ, Macdonald RL. Slow degradation and aggregation in vitro of mutant GABAA receptor gamma2(Q351X) subunits associated with epilepsy. J Neurosci 2010;30(41):13895-905. PMID 20943930
71: Kim SY, Jang SS, Kim JI, et al. Dissecting the phenotypic and genetic spectrum of early childhood-onset generalized epilepsies. Seizure 2019;71:222-8. PMID 31401500
72: Kivity S, Oliver KL, Afawi Z, et al. SCN1A clinical spectrum includes the self-limited focal epilepsies of childhood. Epilepsy Res 2017;131:9-14. PMID 28192756
73: Kruger LC, O'Malley HA, Hull JM, Kleeman A, Patino GA, Isom LL. β1-C121W is down but not out: epilepsy-associated Scn1b-C121W results in a deleterious gain-of-function. J Neurosci 2016;36(23):6213-24. PMID 27277800
74: Kumakura A, Ito M, Hata D, et al. Novel de novo splice-site mutation of SCN1A in a patient with partial epilepsy with febrile seizures plus. Brain Dev 2009;31(2):179-82. PMID 18632234
75: Lachance-Touchette P, Brown P, Meloche C, et al. Novel alpha1 and gamma2 GABAA receptor subunit mutations in families with idiopathic generalized epilepsy. Eur J Neurosci 2011;34(2):237-49. PMID 21714819
76: Lennox-Buchtal MA. Febrile and nocturnal convulsions in monozygotic twins. Epilepsia 1971;12:147-56.
77: Lerche H, Weber YG, Baier H, et al. Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. Neurology 2001;57(7):1191-8. PMID 11591834
78: Li X, Guo S, Liu K, et al. GABRG2 deletion linked to genetic epilepsy with febrile seizures plus affects the expression of GABAA receptor subunits and other genes at different temperatures. Neuroscience 2020;438:116-36. PMID 32418750
79: Lin H, Li J, Wang M, Wang Z, Wang Y, Wu L. Mutation screening of three Chinese families with genetic epilepsy with febrile seizures plus. Neurosci Lett 2011;500(2):123-8. PMID 21704126
80: Ling Y, Wang Y, Jiang X, Yuan C. Mechanism of the promotion of GEFS+ by the STAT3-mediated expression of interleukin-6. Transl Pediatr 2022;11(9):1491-501. PMID 36247897
81: Liu X, Li W, Han T, et al. The finding of a new heterozygous mutation site of the SCN2A gene in a monozygotic twin family carrying and exhibiting genetic epilepsy with febrile seizures plus (GEFS+) using targeted next-generation sequencing. Clin Neurol Neurosurg 2018;169:86-91. PMID 29635106
82: Lossin C, Rhodes TH, Desai RR, et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 2003;23(36):11289-95. PMID 14672992
83: Lossin C, Wang DW, Rhodes TH, Vanoye CG, George AL Jr. Molecular basis of an inherited epilepsy. Neuron 2002;34(6):877-84. PMID 12086636
84: Makinson CD, Dutt K, Lin F, et al. An Scn1a epilepsy mutation in Scn8a alters seizure susceptibility and behavior. Exp Neurol 2016;275 Pt 1:46-58. PMID 26410685
85: Makinson CD, Tanaka BS, Lamar T, Goldin AL, Escayg A. Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance. Neurobiol Dis 2014;68:16-25. PMID 24704313
86: Mantegazza M, Broccoli V. SCN1A/NaV 1.1 channelopathies: mechanisms in expression systems, animal models, and human iPSC models. Epilepsia 2019;60 Suppl 3:S25-38.** PMID 31904127
87: Marco Hernández AV, Tomás Vila M, Caro Llopis A, Monfort S, Martinez F. Case report: novel homozygous likely pathogenic SCN1A variant with autosomal recessive inheritance and review of the literature. Front Neurol 2021;12:784892. PMID 34917021
88: Marini C, Mei D, Parmeggiani L, et al. Protocadherin 19 mutations in girls with infantile-onset epilepsy. Neurology 2010;75(7):646-53. PMID 20713952
89: Marini C, Mei D, Temudo T, et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 2007;48(9):1678-85. PMID 17561957
90: Marini C, Porro A, Rastetter A, et al. HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. Brain 2018;141(11):3160-78. PMID 30351409
91: Mastrangelo M, Midulla F, Moretti C. Actual insights into the clinical management of febrile seizures. Eur J Pediatr 2014;173(8):977-82. PMID 24477659
92: Meisler MH, Kearney J, Escayg A, MacDonald BT, Sprunger LK. Sodium channels and neurological disease: insights from Scn8a mutations in the mouse. Neuroscientist 2001;7(2):136-45. PMID 11496924
93: Meisler MH, O'Brien JE, Sharkey LM. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol 2010;588(Pt 11):1841-8. PMID 20351042
94: Miller IO, Sotero de Menezes MA. SCN1A seizure disorders. 2007 Nov 29 [Updated 2019 Apr 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 2019.** PMID 20301494
95: Moller RS, Wuttke TV, Helbig I, et al. Mutations in GABRB3: from febrile seizures to epileptic encephalopathies. Neurology 2017;88(5):483-92. PMID 28053010
96: Moretti R, Arnaud L, Bouteiller D, et al. SCN1A-related epilepsy with recessive inheritance: two further families. Eur J Paediatr Neurol 2021;33:121-4. PMID 34174751
97: Moulard B, Guipponi M, Chaigne D, Mouthon D, Buresi C, Malafosse A. Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q234-q33. Am J Hum Genet 1999;65:1396-400. PMID 10521305
98: Mrabet H, Belhedi N, Bouchlaka S, El Gaaied A, Mrabet A. GEFS+ is not related to the most common mutations of SCN1B, SCN1A and GABRG2 in two Tunisian families. Neurol Sci 2007;28:311-4. PMID 18175077
99: Mulley JC, Hodgson B, McMahon JM, et al. Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome. Epilepsia 2013;54(9):e122-6. PMID 23895530
100: Myers KA, Burgess R, Afawi Z, et al. De novo SCN1A pathogenic variants in the GEFS+ spectrum: not always a familial syndrome. Epilepsia 2017;58(2):e26-30. PMID 28084635
101: Myers KA, Scheffer IE, Berkovic SF, ILAE Genetics Commission. Genetic literacy series: genetic epilepsy with febrile seizures plus. Epileptic Disord 2018;20(4):232-8.** PMID 30078767
102: Myers KA, Shevell MI, Sébire G. Sudden unexpected death in GEFS+ families with sodium channel pathogenic variants. Epilepsy Res 2019;150:66-9. PMID 30660056
103: Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. N Engl J Med 1976;295:1029-33. PMID 972656
104: Nelson KB, Ellenberg JH. Prognosis in children with febrile seizures. Pediatrics 1978;61:720-7. PMID 662510
105: Ogiwara I, Miyamoto H, Morita N, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007;27:5903-14. PMID 17537961
106: Ohmori I, Ouchida M, Miki T, et al. A CACNB4 mutation shows that altered Cav2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. Neurobiol Dis 2008b;32:349-54. PMID 18755274
107: Oller-Daurella L, Oller LF. Epilepsy with generalized tonic-clonic seizures in childhood. Does a childhood ‘grand mal’ syndrome exist. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 2nd ed. London: John Libbey 1992;161-71.
108: Passamonti C, Petrelli C, Mei D, et al. A novel inherited SCN1A mutation associated with different neuropsychological phenotypes: is there a common core deficit? Epilepsy Behav 2015;43:89-92. PMID 25569746
109: Patino GA, Claes LR, Lopez-Santiago LF, et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 2009;29(34):10764-78. PMID 19710327
110: Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39(1):5-17. PMID 9578007
111: Peycheva V, Ivanova N, Kamenarova K, et al. SCN1A mutation spectrum in a cohort of Bulgarian patients with GEFS+ phenotype. Turk J Pediatr 2020;62(5):711-25. PMID 33108073
112: Poduri A, Wang Y, Gordon D, et al. Novel susceptibility locus at chromosome 6q16.3-22.31 in a family with GEFS+. Neurology 2009;73(16):1264-72. PMID 19841378
113: Polizzi A, Incorpora G, Pavone P, et al. Generalised epilepsy with febrile seizures plus (GEFS(+)): molecular analysis in a restricted area. Childs Nerv Syst 2012;28(1):141-5. PMID 22011963
114: Puranam RS, He XP, Yao L, et al. Disruption of Fgf13 causes synaptic excitatory-inhibitory imbalance and genetic epilepsy and febrile seizures plus. J Neurosci 2015;35(23):8866-81. PMID 26063919
115: Rigbye KA, van Hasselt PM, Burgess R, et al. Is FGF13 a major contributor to genetic epilepsy with febrile seizures plus? Epilepsy Res 2016;128:48-51. PMID 27810516
116: Riva A, Coppola A, Balagura G, et al. Temporal-parietal-occipital epilepsy in GEFS+ associated with SCN1A mutation. Epileptic Disord 2021;23(2):397-401. PMID 33851920
117: Rubinstein M, Westenbroek RE, Yu FH, Jones CJ, Scheuer T, Catterall WA. Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. Neurobiol Dis 2015;73:106-117. PMID 25281316
118: Sager G, Cetin BS, Cag Y, Pinar ZV, Akin Y. Auditory phoneme discrimination, articulation, and language disorders in patients with genetic epilepsy with febrile seizures plus: a case control study. Epilepsy Behav 2022;129:108626. PMID 35231857
119: Salgueiro-Pereira AR, Duprat F, Poushinha PA, et al. A two-hit story: Seizures and genetic mutation interaction sets phenotype severity in SCN1A epilepsies. Neurobiol Dis 2019;125:31-44. PMID 30659983
120: Scheffer I, Berkovic S. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 1997;120:479-90.** PMID 9126059
121: Scheffer I, Berkovic S. Generalized (genetic) epilepsy with febrile seizures plus. In: Engel JJ, Pedley T, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott, Williams & Wilkins, 2008:2553-8.
122: Scheffer IE, Harkin LA, Dibbens LM, Mulley JC, Berkovic SF. Neonatal epilepsy syndromes and generalized epilepsy with febrile seizures plus (GEFS+). Epilepsia 2005;46 Suppl 10:41-7. PMID 16359471
123: Scheffer IE, Harkin LA, Grinton BE, et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 2007;130(Pt 1):100-9. PMID 17020904
124: Scheffer IE, Nabbout R. SCN1A-related phenotypes: epilepsy and beyond. Epilepsia 2019;60 Suppl 3:S17-24. PMID 31904117
125: Scheffer IE, Wallace R, Mulley JC, Berkovic SF. Clinical and molecular genetics of myoclonic-astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain Dev 2001;23(7):732-5. PMID 11701287
126: Scheffer IE, Zhang Y. Genetic epilepsy with febrile seizures plus. In: Shorvon SD, Andermann F, Guerrini R, editors. The Causes of Epilepsy. Cambridge University Press, 2011.
127: Schubert J, Siekierska A, Langlois M, et al. Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. Nat Genet 2014;46(12):1327-32. PMID 25362483
128: Selmer KK, Egeland T, Solaas MH, et al. Genetic screening of Scandinavian families with febrile seizures and epilepsy or GEFS+. Acta Neurol Scand 2008;117:289-92. PMID 17927801
129: Shafrir Y. Response to: Deng L, Ma A, Wood N, Ardern-Holmes S. Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine. Seizure 2020;78:49-52.** PMID 32659653
130: Shi X, Yasumoto S, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev 2009;31(10):758-62. PMID 19783390
131: Shi X, Yasumoto S, Kurahashi H, et al. Clinical spectrum of SCN2A mutations. Brain Dev 2012a;34(7):541-5. PMID 22029951
132: Shimizu H, Miyazaki H, Ohsawa N, et al. Structure-based site-directed photo-crosslinking analyses of multimeric cell-adhesive interactions of voltage-gated sodium channel β subunits. Sci Rep 2016;6:26618. PMID 27216889
133: Shinnar S, Bello JA, Chan S, et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology 2012;28;79(9):871-7. PMID 22843278
134: Singh NA, Pappas C, Dahle EJ, et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 2009;5(9):e1000649. PMID 19763161
135: Singh R, Andermann E, Whitehouse WP. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+. Epilepsia 2001;42:837-44. PMID 11488881
136: Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 1999;45(1):75-81. PMID 9894880
137: Skjei KL, Church EW, Harding BN, et al. Clinical and histopathological outcomes in patients with SCN1A mutations undergoing surgery for epilepsy. J Neurosurg Pediatr 2015;16(6):668-74. PMID 26339958
138: Sugawara T, Tsurubuchi Y, Agarwala KL, et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci U S A 2001;98(11):6384-9. Erratum in: Proc Natl Acad Sci U S A 2001;98(18):10515. PMID 11371648
139: Sugiura Y, Ogiwara I, Hoshi A, Yamakawa K, Ugawa Y. Different degrees of loss of function between GEFS+ and SMEI Na(v) 1.1 missense mutants at the same residue induced by rescuable folding defects. Epilepsia 2012;53(6):e111-4. PMID 22525008
140: Sun H, Zhang Y, Liang J, et al. SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus. J Hum Genet 2008;53(8):769-74. PMID 18566737
141: Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain 2019;142(8):2303-18.** PMID 31302675
142: Tian M, Mei D, Freri E, et al. Impaired surface αβγ GABA(A) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation. Neurobiol Dis 2013;50:135-41. PMID 23069679
143: Tian Y, Hou C, Wang XY, et al. A novel inherited STX1B mutation associated with generalized epilepsy with febrile seizures plus: a family analysis and literature review [Article in Chinese]. Zhonghua Er Ke Za Zhi 2019;57(3):206-10. PMID 30818898
144: Till A, Zima J, Fekete A, et al. Mutation spectrum of the SCN1A gene in a Hungarian population with epilepsy. Seizure 2020 Jan;74:8-13. PMID 31765958
145: Veggiotti P, Cardinali S, Montalenti E, Gatti A, Lanzi G. Generalized epilepsy with febrile seizures plus and severe myoclonic epilepsy in infancy: a case report of two Italian families. Epileptic Disord 2001;3:29-32. PMID 11313220
146: Volkers L, Kahlig KM, Verbeek NE, et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome. Eur J Neurosci 2011;34(8):1268-75. PMID 25591652
147: Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 2001a;28(1):49-52. PMID 11326275
148: Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet 2001b;68(4):859-65. PMID 11254444
149: Wallace RH, Scheffer IE, Parasivam G, et al. Generalized epilepsy with febrile seizures plus: mutation of the sodium channel subunit SCN1B. Neurology 2002;58:1426-9. PMID 12011299
150: Wallace RH, Wang DW, Singh R, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+ -channel beta1 subunit gene SCN1B. Nat Genet 1998;19(4):366-70. PMID 9697698
151: Weber YG, Jacob M, Weber G, Lerche H. A BFIS-like syndrome with late onset and febrile seizures: suggestive linkage to chromosome 16p11.2-16q12.1. Epilepsia 2008;49(11):1959-64. PMID 18479394
152: Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia 2022;63(7):1761-77. PMID 35490361
153: Xie Y, Ng NN, Safrina OS, et al. Comparisons of dual isogenic human iPSC pairs identify functional alterations directly caused by an epilepsy associated SCN1A mutation. Neurobiol Dis 2020;134:104627. PMID 31786370
154: Xu R, Thomas EA, Gazina EV, et al. Generalized epilepsy with febrile seizures plus-associated sodium channel beta 1 subunit mutations severely reduce beta subunit-mediated modulation of sodium channel function. Neuroscience 2007;148(1):164-74. PMID 17629415
155: Xu XJ, Zhang YH, Sun HH, Liu XY, Wu HS, Wu XR. [Phenotype and SCN1A gene mutation screening in 39 families with generalized epilepsy with febrile seizures plus]. Zhonghua Er Ke Za Zhi 2012;50(8):580-6. PMID 23158734
156: Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006;9:1142-9. PMID 16921370
157: Zhang YH, Burgess R, Malone JP, et al. Genetic epilepsy with febrile seizures plus: refining the spectrum. Neurology 2017;89(12):1210-9. PMID 28842445
158: Zhang T, Chen M, Zhu A, Zhang X, Fang T. Novel mutation of SCN9A gene causing generalized epilepsy with febrile seizures plus in a Chinese family. Neurol Sci 2020;41(7):1913-7. PMID 32062735
159: Zhu Z, Bolt E, Newmaster K, et al. SCN1B genetic variants: a review of the spectrum of clinical phenotypes and a report of early myoclonic encephalopathy. Children (Basel) 2022;9(10):1507. PMID 36291443
160: Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349-97.** PMID 35503712

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Eleni Panagiotakaki MD PhD

Dr. Panagiotakaki of University Hospitals of Lyon has no relevant financial relationships to disclose.
See Profile
Maria Papadopoulou MD

Dr. Papadopoulou of Papageorgiou University Hospital of Thessaloniki, Greece, has no relevant financial relationships to disclose.
See Profile
Alexis Arzimanoglou MD

Dr. Arzimanoglou of University Hospitals of Lyon has no relevant financial relationships to disclose.
See Profile

Editor

Jerome Engel Jr MD PhD

Dr. Engel of the David Geffen School of Medicine at the University of California, Los Angeles, has no relevant financial relationships to disclose.
See Profile

Former Authors

Florence Renaldo MD and Petra Grdjan MD

Patient Profile

Age range of presentation: 1 month to 12 years
Sex preponderance: male=female
Heredity: Heredity may be a factor:

Autosomal dominant

Autosomal recessive

Sex-linked dominant

De novo mutations

Copy number variants
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: None selectively affected

ICD & OMIM codes

ICD-9: Generalized convulsive epilepsy: 345.1
ICD-10: Generalized idiopathic epilepsy and epileptic syndromes: G40.3
OMIM: Genetic epilepsy with febrile seizures plus: #604233

Generalized epilepsy with febrile seizures plus, type 2; GEFSP2: #604403

Generalized epilepsy with febrile seizures plus, type 4; GEFSP4: %609800

Febrile seizures, familial: #607681

Generalized epilepsy with febrile seizures plus, type 6; GEFSP6: %612279

Epilepsy, idiopathic generalized, susceptibility to, 10; EIG10: #613060

Generalized epilepsy with febrile seizures plus, type 8; GEFSP8: %613828

Generalized epilepsy with febrile seizures plus, type 7; GEFSP7: #613863

Generalized epilepsy with febrile seizures plus, type 9; GEFSP9: #616172

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Genetic epilepsy with febrile seizures plus

Associated Disorders

Dravet syndrome
Febrile seizures
Febrile seizures plus
Focal seizures
Generalized seizures
- Myoclonic-astatic seizures
- Unclassified epilepsy
- Unclassified seizures

Differential Diagnosis

Common febrile seizures
Dravet syndrome
Myoclonic atonic epilepsy
inherited metabolic epilepsies (pyridoxine-dependent epilepsy, Glut-1 transporter deficiency)

Also Relevant

Benign infantile seizures
Dravet syndrome
Epilepsy with myoclonic-atonic seizures
Febrile seizures
Myoclonic epilepsy in infancy

Clinical Categories

Patient Handouts

Dravet syndrome

Web References

Guidelines

Testing

Generalized Epilepsy with Febrile Seizures Plus

Genetic epilepsy with febrile seizures plus …

Genetic epilepsy with febrile seizures plus

Introduction

Overview

Key points

Historical note and terminology

Table 1. Genetic Loci and Most Commonly Known Genes Associated with GEFS+

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Photosensitive occipital lobe epilepsy

Breath-holding spells

Intermittent explosive disorder

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Genetic epilepsy with febrile seizures plus

Introduction

Overview

Key points

Historical note and terminology

Table 1. Genetic Loci and Most Commonly Known Genes Associated with GEFS+

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Photosensitive occipital lobe epilepsy

Breath-holding spells

Intermittent explosive disorder

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

This is an article preview.
Start a Free Account
to access the full version.